Caldera Medical, Inc. on October 8th, 2024, announced the acquisition of UVision 360, Inc. Caldera Medical develops medical devices for women’s health, including surgical products for the treatment of stress urinary incontinence, pelvic floor disorders, pelvic organ prolapse, and hysteroscopic removal of intrauterine tissue. UVision 360 is a developer of in-office hysteroscopy systems for evaluating and treating uterine conditions.
The acquisition is purported to bolster Caldera Medical’s minimally invasive solutions, particularly in the realm of advanced hysteroscopy and its Benesta® product line. Caldera Medical reports that it expects this acquisition to broaden its portfolio for diagnosis and treatment of polyps, fibroids, and intrauterine pathology through the introduction of UVision 360’s LUMINELLE® technology with the Benesta® line to enhance procedural capabilities for gynecologic surgeons.
The LUMINELLE® DTx Hysteroscopy System reportedly uses separately controlled fluid inflow and outflow, Rotowings enabling 360° rotation, and the RotoSheath’s graduated tip size and hydrodilation from the inflow valve, to assist in hysteroscopy and cystoscopy procedures. UVision 360’s new LUMINELLE® Bx system purports to allow physicians to achieve a more accurate and precise diagnosis through its on-demand biopsy technology with integrated visualization.
Regarding the acquisition, Bryon Merade, CEO of Caldera Medical, stated:
Caldera Medical’s acquisition of UVision 360 follows Caldera Medical’s announced acquisition of Atlantic Therapeutics, completed in September 2023. Caldera’s acquisition of Atlantic Therapeutics added the Innovo® device to their technology offerings, for treating urinary incontinence for at-home users via electrical muscle stimulation.
Erich Dreyer, co-founder and engineer involved with the LUMINELLE® technology, stated the following about the acquisition:
A press release regarding the acquisition is available here.